CA3108079C - Pegylated tetanus neurotoxins and treatment of hypotonia - Google Patents

Pegylated tetanus neurotoxins and treatment of hypotonia Download PDF

Info

Publication number
CA3108079C
CA3108079C CA3108079A CA3108079A CA3108079C CA 3108079 C CA3108079 C CA 3108079C CA 3108079 A CA3108079 A CA 3108079A CA 3108079 A CA3108079 A CA 3108079A CA 3108079 C CA3108079 C CA 3108079C
Authority
CA
Canada
Prior art keywords
tent
peg
pegylated
kda
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3108079A
Other languages
English (en)
French (fr)
Other versions
CA3108079A1 (en
Inventor
Thomas Mclean
Peter SMOOKER
Luke NORBURY
Peter COLOE
Russell CONDUIT
Anthony Sasse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Snoretox Pty Ltd
Original Assignee
Snoretox Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018902779A external-priority patent/AU2018902779A0/en
Application filed by Snoretox Pty Ltd filed Critical Snoretox Pty Ltd
Priority to CA3167665A priority Critical patent/CA3167665A1/en
Publication of CA3108079A1 publication Critical patent/CA3108079A1/en
Application granted granted Critical
Publication of CA3108079C publication Critical patent/CA3108079C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24068Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
CA3108079A 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia Active CA3108079C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3167665A CA3167665A1 (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018902779A AU2018902779A0 (en) 2018-07-31 Composition and method
AU2018902779 2018-07-31
PCT/AU2019/050793 WO2020024002A1 (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3167665A Division CA3167665A1 (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Publications (2)

Publication Number Publication Date
CA3108079A1 CA3108079A1 (en) 2020-02-06
CA3108079C true CA3108079C (en) 2023-10-10

Family

ID=69230503

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3108079A Active CA3108079C (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia
CA3167665A Pending CA3167665A1 (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3167665A Pending CA3167665A1 (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Country Status (12)

Country Link
US (1) US20210353724A1 (https=)
EP (2) EP3830110A4 (https=)
JP (3) JP2021533201A (https=)
KR (1) KR20210040407A (https=)
CN (2) CN120661638A (https=)
AU (1) AU2019315327B2 (https=)
BR (1) BR112021001520A2 (https=)
CA (2) CA3108079C (https=)
MX (1) MX2021001181A (https=)
NZ (1) NZ772266A (https=)
SG (1) SG11202100646SA (https=)
WO (1) WO2020024002A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240268895A1 (en) 2023-02-15 2024-08-15 Canon Medical Systems Corporation X-ray diagnostic apparatus, x-ray diagnostic system, and x-ray diagnostic method

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003200441B2 (en) * 1998-04-29 2006-07-06 Allergan, Inc. Compositions and methods for modulating neural sprouting
GB9914861D0 (en) * 1999-06-25 1999-08-25 Imperial College Tetanus toxin polypeptides
AU2001270219A1 (en) * 2000-06-28 2002-01-08 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
WO2003000193A2 (en) * 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
EP1531859A4 (en) * 2002-05-31 2005-12-07 Univ Jefferson COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT
WO2008024879A1 (en) * 2006-08-25 2008-02-28 University Of Maryland, Baltimore Use of tetanus toxin to amplify inadequate voluntary muscle contraction or to improve muscle tone in an animal actively vaccinated against the toxin and a regimen for treatment
EP2425251B1 (en) * 2009-04-27 2017-10-25 Merz Pharma GmbH & Co. KGaA Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
LT2547364T (lt) * 2010-03-15 2017-03-27 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Peptidai, konjugatai ir vakcinos imunogeniškumo padidinimo būdas
WO2016001762A1 (en) 2014-07-02 2016-01-07 Spherium Biomed S.L. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)
BR112018003782A2 (pt) * 2015-08-27 2018-09-25 Ipsen Pharma Sas composições e métodos para o tratamento da dor
CN106692963B (zh) * 2016-12-28 2020-12-22 中国人民解放军军事医学科学院生物工程研究所 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗
EP3723784A4 (en) * 2017-12-15 2022-01-12 The Medical College of Wisconsin, Inc. USE OF MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS
JP2023513895A (ja) * 2020-02-03 2023-04-04 スノーレトックス リミテッド 組成物及び方法

Also Published As

Publication number Publication date
NZ772266A (en) 2022-09-30
MX2021001181A (es) 2021-04-19
JP2024014975A (ja) 2024-02-01
AU2019315327B2 (en) 2024-05-09
CN112638937A (zh) 2021-04-09
AU2019315327A1 (en) 2021-02-11
EP4134133A1 (en) 2023-02-15
JP2026026159A (ja) 2026-02-16
WO2020024002A1 (en) 2020-02-06
CA3167665A1 (en) 2020-02-06
KR20210040407A (ko) 2021-04-13
NZ789962A (en) 2025-07-25
JP7786745B2 (ja) 2025-12-16
US20210353724A1 (en) 2021-11-18
SG11202100646SA (en) 2021-02-25
BR112021001520A2 (pt) 2021-04-20
CA3108079A1 (en) 2020-02-06
EP3830110A1 (en) 2021-06-09
CN120661638A (zh) 2025-09-19
JP2021533201A (ja) 2021-12-02
EP3830110A4 (en) 2022-03-02
CN112638937B (zh) 2025-06-17

Similar Documents

Publication Publication Date Title
JP3523879B2 (ja) 輸送タンパク質用クロストリジウム属細菌毒素の修飾
AU2009286973B2 (en) Clostridial neurotoxins with altered persistency
ES2341140T3 (es) Tratamiento de trastornos y afecciones neuromusculares con un seropositivo botulinico diferente.
RU2676729C2 (ru) Новый аналог инсулина и его применение
US8445650B2 (en) Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
Kiss et al. Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230
EA039105B1 (ru) Катионные нейротоксины
JP2026026159A (ja) Peg化破傷風神経毒素および筋緊張低下の治療
AU2010241253B2 (en) Synthetic active peptide fragments
JP7646555B2 (ja) 振戦治療のためのボツリヌス神経毒素の新規用途
US20230057367A1 (en) Composition and method
JP2019531698A (ja) 活性化クロストリジウム神経毒の製造
US10149900B2 (en) Immunogenic compositions and vaccines derived from bacterial surface receptor proteins
JP2022508713A (ja) ワクチンポリペプチド組成物および方法
CN121532207A (zh) 用于治疗特应性皮炎的主动免疫
KR20230129223A (ko) Sars-cov-2 수용체 결합 도메인과 담체 단백질의 공유결합체 및 그것을 함유하는 백신 조성물
JP2011084559A (ja) 改変融合タンパク質
EA048316B1 (ru) Ковалентные конъюгаты рецептор-связывающего домена sars-cov-2 и белка-носителя и содержащие их вакцинные композиции
JPH10120591A (ja) 免疫寛容誘導剤
NZ715570B2 (en) Cationic neurotoxins
CZ20001399A3 (cs) Prostředky a způsoby pro systémové podání orálních vakcín a terapeutických činidel

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211222

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250530

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250723

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250723